Holy Grail Pre-Workout: Label Analysis and Legal Status

A label analysis of Holy Grail Pre-workout: 16 ingredients per 10 g scoop, including DMAA, DMHA and higenamine, with the research on each and their legal and anti-doping status.

Holy Grail pre-workout and creatine

Holy Grail Pre-workout at a glance

Holy Grail Pre-workout is a high-stimulant powder from Holy Grail Supplements, sold as an “all in one pre-workout”. One 10 g scoop lists 16 ingredients, from citrulline malate and beta-alanine to caffeine, DMAA, DMHA, higenamine and yohimbine, with 30 servings per 300 g tub. It is only for experienced lifters who know how they react to strong stimulants, and not for drug-tested athletes.

  • Formula: caffeine, beta-alanine and citrulline malate have human trials on exercise; DMHA has animal studies only, and higenamine, hordenine, synephrine, noopept and Mucuna were not assessed.
  • Dosing: every ingredient is listed with its amount, with no proprietary blend. Not scored, because we do not rate amounts of DMAA, DMHA, higenamine, hordenine, synephrine, noopept, Mucuna (L-DOPA) or yohimbine.
  • Effect: not rated: label analysis.
  • Value: not rated.

Updated 21 November 2026.

This is a label analysis. We have not used Holy Grail Pre-workout for this review; the formula comes from the supplement facts panel published for the product in November 2026. More on our method: how we review.

Which version of Holy Grail Pre-workout is this

This review covers the 300 g tub. The panel gives a 10 g serving, 30 servings per container and one heading for all 16 ingredients, “Holy Grail Workout Formula”. It does not say which market the product is made for, so we cannot tell whether a US and an EU version differ.

What’s in Holy Grail Pre-workout

Ingredient (label spelling)Per 10 g scoopEvidence
Citrulline Malate3,000 mgHuman trials
Beta Alanine2,500 mgHuman trials
Agmatine Sulfate1,500 mgHuman trials, none on exercise
L-Tyrosine500 mgHuman trials
Caffeine Anhydrous300 mgHuman trials
Theobromine200 mgHuman trials
2-Aminoisoheptane100 mgAnimal studies
1.3 DMAA100 mgHuman trials (small studies)
Synephrine Hcl65 mgNot assessed
Hordenine60 mgNot assessed
Higenamine HcL55 mgNot assessed
Mucuna Prurines (Std. 15% L-Dopa)50 mgNot assessed
Alpha GPC50 mgHuman trials
L-Theanine50 mgHuman trials
Noopept20 mgNot assessed
Yohimbine Hcl2 mgHuman trials

Sixteen ingredients, all with their amounts and no proprietary blend. By what they do, they fall into three groups: a training formula, a stim formula and a focus formula.

How the Holy Grail formula works

The training formula: citrulline malate, beta-alanine and agmatine

Citrulline malate (3,000 mg) pairs the amino acid citrulline with malic acid. The body absorbs citrulline readily and converts at least part of it into arginine, the raw material for nitric oxide. A 2021 meta-analysis pooled eight placebo-controlled trials with 137 participants, most of them strength-trained men. Taking 6 to 8 g of citrulline malate 40 to 60 minutes before training raised repetitions to failure by 6.4% on average, a small effect.

Beta-alanine (2,500 mg) is the amino acid muscles use to build carnosine, a buffer against the acid that builds up in hard efforts. The ISSN position stand concludes that 4 to 6 g a day for at least two to four weeks improves performance. The clearest effects are in efforts of one to four minutes. The stand names tingling of the skin as the only reported side effect, common above 800 mg in one serving of a standard form.

Agmatine sulfate (1,500 mg) is a compound the body makes from arginine. In enzyme experiments it blocked the enzymes that make nitric oxide instead of feeding them. The human research is medical, and we found no trial of agmatine on exercise performance in people (PubMed search, 21 November 2026). The largest trial, in people with sciatica, used 2.67 g of agmatine sulfate a day for 14 days.

The stim formula: caffeine and theobromine

Caffeine (300 mg, as caffeine anhydrous) blocks adenosine receptors in the brain, which raises alertness and dampens pain. The ISSN position stand found that it improves performance in many, though not all, studies. The gains are small to moderate and cover muscular endurance, strength, sprinting and jumping. The stand reports consistent effects at 3 to 6 mg per kg of body mass. It adds that pre-workouts with caffeine have improved both anaerobic and aerobic performance.

Theobromine (200 mg) is a methylxanthine from cocoa, related to caffeine. It blocks adenosine receptors and inhibits phosphodiesterases. In 24 young men, 100, 200 or 400 mg of theobromine in a cocoa drink did not consistently change mood or vigilance. In the same study, 100 mg of caffeine reduced fatigue. In 80 healthy adults, 250 mg had limited effects, 500 and 1,000 mg worsened mood, and heart rate rose with the dose. A 2021 systematic review found one exercise study: theobromine beat placebo and matched caffeine in a 3 km treadmill time trial.

The other stimulants

For the six compounds below, we give the label amount, what each compound is and how it acts, with no amounts from studies and no “typical” amounts.

2-Aminoisoheptane (100 mg) is a name the FDA gives as a synonym of DMHA. Two related compounds are sold as DMHA; octodrine, one of the two, is a central nervous system stimulant first developed as a nasal decongestant. Its pharmacology comes from animal studies, and we found no controlled trial of DMHA in people (PubMed search, 21 November 2026).

DMAA (100 mg, listed as “1.3 DMAA”) is 1,3-dimethylamylamine, which the FDA describes as an amphetamine derivative once approved as a nasal decongestant. According to the FDA, it narrows blood vessels and arteries and can raise blood pressure. The FDA links it to problems from shortness of breath to heart attack.

Synephrine (65 mg, as the hydrochloride) is an amine whose p-form is the main plant compound of bitter orange (Citrus aurantium). It acts on several adrenergic and serotonergic receptors. Synephrine exists in three forms, and the label does not say which one it uses.

Hordenine (60 mg), or N,N-dimethyltyramine, is a compound found in sprouting barley. In animal experiments it acted indirectly, by releasing noradrenaline. In rats and dogs it raised blood pressure and the force of the heartbeat, but the authors describe these effects as short-lived and seen only after high doses.

Higenamine (55 mg, as the hydrochloride) is a plant compound found in species such as lotus (Nelumbo nucifera) and Aconitum. Laboratory, animal and a few clinical studies suggest it acts in part as a beta-2 agonist, a drug class used for asthma.

Yohimbine (2 mg, as the hydrochloride) is an alkaloid from yohimbe bark. It blocks alpha-2 adrenergic receptors, a brake on fat release; in healthy men, oral yohimbine raised blood noradrenaline by 40 to 50% and mobilised fat.

The focus formula

L-tyrosine (500 mg) is the amino acid the body uses to make dopamine and noradrenaline. In one study, tyrosine helped 19 volunteers keep their working memory in cold water. In another, it eased the decline on a psychomotor task during a night without sleep. The cold study gave 150 mg per kg of body weight before each of two immersions; the sleep-loss study gave 150 mg per kg in two doses. A 2023 meta-analysis of 8 studies in physically active people found no effect on endurance performance.

Alpha-GPC (50 mg) supplies choline, the raw material for acetylcholine, a messenger linked to muscle contraction and cognition. In 13 college-aged men, 600 mg a day for six days raised peak force in the isometric mid-thigh pull compared with placebo. In 20 resistance-trained men, a single 315 or 630 mg dose improved a Stroop test score, while jumps and bench press throws did not differ from placebo.

L-theanine (50 mg) is an amino acid from tea. A 2025 meta-analysis pooled 16 randomised trials of tea, L-theanine or both compounds in 484 healthy adults. Against placebo, L-theanine with caffeine brought small to moderate gains in vigilance and attention-switching accuracy in the second hour, though confidence intervals were often wide. These trials used a median of 82 mg of L-theanine with 89 mg of caffeine.

Noopept (20 mg), or omberacetam, is an active pharmaceutical ingredient from the nootropic family, grouped with the racetams although its structure differs from piracetam’s. Its proposed mechanism involves several neurotransmitter systems; in rats, it raised the expression of the nerve growth factors NGF and BDNF in the hippocampus.

Mucuna pruriens (50 mg, listed as “Mucuna Prurines (Std. 15% L-Dopa)”) is a legume naturally rich in levodopa (L-DOPA). Levodopa is the basis of standard medicines for Parkinson’s disease. In a 2026 review, two neurologists call Mucuna a potent dopaminergic therapy that needs the same caution as levodopa medicines. The 50 mg on the label is the weight of the extract, not of L-DOPA.

Who Holy Grail Pre-workout is for

It is for experienced lifters who know how they react to strong stimulants and want training, stim and focus ingredients in one scoop. It is not for drug-tested athletes. In the US, the FDA says DMAA products sold as supplements are illegal, and in the UK, the MHRA has called them unlicensed medicines. One serving lists 300 mg of caffeine anhydrous. EFSA considers single doses of caffeine up to 200 mg of no safety concern for healthy adults, and up to 400 mg a day except in pregnant women. The same scoop adds DMAA, DMHA, synephrine, hordenine, higenamine and yohimbine. The FDA warns that DMAA can be a health risk, especially with other stimulants such as caffeine. Count the caffeine from coffee and other products on training days. Check with a doctor first if you have high blood pressure, a heart condition or anxiety, or take any medication, including medicines for Parkinson’s disease, since Mucuna supplies levodopa.

Legal and anti-doping status

Status checked on 21 November 2026.

  • DMAA: the 2026 and 2027 WADA Lists name 4-methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexaneamine) in class S6, stimulants, prohibited in competition. In 2017 the MHRA said that DMAA is found in unlicensed medicines marketed as sports supplements and that it takes urgent action to remove them from sale. The FDA says DMAA products sold as supplements are illegal.
  • 2-aminoisoheptane (DMHA): WADA names octodrine (1,5-dimethylhexylamine), one of two compounds sold as DMHA, in class S6; the class also covers stimulants it does not name. The label gives no full chemical name. The FDA considers DMHA an unsafe food additive and lists 2-aminoisoheptane among its other names.
  • Higenamine: named by WADA in class S3, beta-2 agonists, prohibited at all times. In May 2022 the FDA sent warning letters over supplements with higenamine or hordenine, among other ingredients. It cited concern about higenamine’s potential effects on the cardiovascular system.
  • Hordenine: not named on the 2026 or 2027 WADA List. Class S6 names “phenethylamine and its derivatives” and covers stimulants it does not name; whether hordenine falls under it is for an anti-doping organisation to decide.
  • Yohimbine: the EU prohibits yohimbe bark and its preparations in foods, and yohimbine hydrochloride is the active substance of medicines authorised in five EU countries. The MHRA has said that products containing yohimbine would normally be controlled as prescription-only medicines in the UK. Not named on the 2026 or 2027 WADA List.
  • Noopept (omberacetam): not named on the 2026 or 2027 WADA List, and not in the European Medicines Agency’s database of medicines authorised in the EU and EEA. In the UK, it was among the products the MHRA seized in a 2014 action against unlicensed “smart drugs”.
  • Mucuna (L-DOPA): levodopa is the active substance of medicines authorised in every EU and EEA country, according to the EMA database. The FDA lists L-DOPA among ingredients excluded from the US definition of a dietary supplement. Neither Mucuna nor levodopa is named on the 2026 or 2027 WADA List.
  • Caffeine and synephrine: on WADA’s Monitoring Program; the 2026 and 2027 Lists state that they are not considered prohibited substances. Theobromine, agmatine, alpha-GPC and the amino acids on this label are not named on either List.

Not for drug-tested athletes: DMAA and octodrine, one of two compounds sold as DMHA, are prohibited in competition, and higenamine is prohibited at all times. Status differs by country and changes over time, so check the rules where you live.

This review replaces an earlier version of this article. That version also covered the brand’s yohimbine and creatine products, and it gave serving advice and safety claims that our sources do not support.

Sources

  1. Product label: Holy Grail Pre-workout 300 g supplement facts panel, manufacturer’s label graphic as shown on a retailer’s product page, November 2026. Front label from the same page. Read on 21 November 2026.
  2. Schwedhelm E, Maas R, Freese R, et al. (2008). Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol, 65(1), 51–59. PMID: 17662090.
  3. Galea E, Regunathan S, Eliopoulos V, et al. (1996). Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J, 316(Pt 1), 247–249. PMID: 8645212.
  4. Vårvik FT, Bjørnsen T, Gonzalez AM (2021). Acute Effect of Citrulline Malate on Repetition Performance During Strength Training: A Systematic Review and Meta-Analysis. Int J Sport Nutr Exerc Metab, 31(4), 350–358. PMID: 34010809.
  5. Trexler ET, Smith-Ryan AE, Stout JR, et al. (2015). International society of sports nutrition position stand: Beta-Alanine. J Int Soc Sports Nutr, 12, 30. PMID: 26175657.
  6. Keynan O, Mirovsky Y, Dekel S, et al. (2010). Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Med, 11(3), 356–368. PMID: 20447305.
  7. Guest NS, VanDusseldorp TA, Nelson MT, et al. (2021). International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr, 18(1), 1. PMID: 33388079.
  8. European Food Safety Authority. Caffeine. Topic page summarising the 2015 Scientific Opinion on the safety of caffeine (EFSA Journal, 13(5), 4102). Accessed 21 November 2026.
  9. Martínez-Pinilla E, Oñatibia-Astibia A, Franco R (2015). The relevance of theobromine for the beneficial effects of cocoa consumption. Front Pharmacol, 6, 30. PMID: 25750625.
  10. Judelson DA, Preston AG, Miller DL, et al. (2013). Effects of theobromine and caffeine on mood and vigilance. J Clin Psychopharmacol, 33(4), 499–506. PMID: 23764688.
  11. Baggott MJ, Childs E, Hart AB, et al. (2013). Psychopharmacology of theobromine in healthy volunteers. Psychopharmacology (Berl), 228(1), 109–118. PMID: 23420115.
  12. Kennedy M (2021). Effects of theophylline and theobromine on exercise performance and implications for competition sport: A systematic review. Drug Test Anal, 13(1), 36–43. PMID: 33188564.
  13. Catalani V, Prilutskaya M, Al-Imam A, et al. (2018). Octodrine: New Questions and Challenges in Sport Supplements. Brain Sci, 8(2), 34. PMID: 29461475.
  14. U.S. Food and Drug Administration. DMHA in Dietary Supplements. Content current as of 6 March 2023. Accessed 21 November 2026.
  15. U.S. Food and Drug Administration. DMAA in Products Marketed as Dietary Supplements. Content current as of 22 February 2023. Accessed 21 November 2026.
  16. Ruiz-Moreno C, Del Coso J, Giráldez-Costas V, et al. (2021). Effects of p-Synephrine during Exercise: A Brief Narrative Review. Nutrients, 13(1), 233. PMID: 33467423.
  17. Rossato LG, Costa VM, Limberger RP, et al. (2011). Synephrine: from trace concentrations to massive consumption in weight-loss. Food Chem Toxicol, 49(1), 8–16. PMID: 21075161.
  18. Hapke HJ, Strathmann W (1995). [Pharmacological effects of hordenine]. Dtsch Tierarztl Wochenschr, 102(6), 228–232. In German, with an English abstract. PMID: 8582256.
  19. Rangelov Kozhuharov V, Ivanov K, Ivanova S (2022). Higenamine in Plants as a Source of Unintentional Doping. Plants (Basel), 11(3), 354. PMID: 35161335.
  20. Hudzik TJ, Patel M, Brown A (2021). β2-Adrenoceptor agonist activity of higenamine. Drug Test Anal, 13(2), 261–267. PMID: 33369180.
  21. Sun J, Chen P (2012). Chromatographic fingerprint analysis of yohimbe bark and related dietary supplements using UHPLC/UV/MS. J Pharm Biomed Anal, 61, 142–149. PMID: 22221902.
  22. Galitzky J, Taouis M, Berlan M, et al. (1988). Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest, 18(6), 587–594. PMID: 2906290.
  23. Fernstrom JD, Fernstrom MH (2007). Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr, 137(6 Suppl 1), 1539S–1547S. PMID: 17513421.
  24. Mahoney CR, Castellani J, Kramer FM, et al. (2007). Tyrosine supplementation mitigates working memory decrements during cold exposure. Physiol Behav, 92(4), 575–582. PMID: 17585971.
  25. Neri DF, Wiegmann D, Stanny RR, et al. (1995). The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med, 66(4), 313–319. PMID: 7794222.
  26. Solon-Júnior LJF, Boullosa Alvarez DA, Martinez Gonzalez B, et al. (2023). The effect of tyrosine supplementation on whole-body endurance performance in physically active population: A systematic review and meta-analysis including GRADE qualification. J Sports Sci, 41(22), 2045–2053. PMID: 38290812.
  27. Kerksick CM (2024). Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients, 16(23), 4240. PMID: 39683633.
  28. Bellar D, LeBlanc NR, Campbell B (2015). The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. J Int Soc Sports Nutr, 12, 42. PMID: 26582972.
  29. Payne ER, Aceves-Martins M, Dubost J, et al. (2025). Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutr Rev, 83(10), 1873–1891. PMID: 40314930.
  30. Araj SK, Szeleszczuk Ł, Gubica T, et al. (2025). Physicochemical and structural analysis of N-phenylacetyl-L-prolylglycine ethyl ester (Noopept) – An active pharmaceutical ingredient with nootropic activity. J Pharm Biomed Anal, 252, 116474. PMID: 39298839.
  31. Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med, 146(3), 334–337. PMID: 19240853.
  32. Cilia R, Katzenschlager R (2026). “To Bean or Not to Bean”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens. J Parkinsons Dis, 16(4), 788–794. PMID: 42053204.
  33. U.S. Food and Drug Administration (2022). FDA Sends Warning Letters to Multiple Companies for Illegally Selling Adulterated Dietary Supplements. Constituent update, 9 May 2022, content current as of 11 May 2022. Accessed 21 November 2026.
  34. U.S. Food and Drug Administration. Information on Select Dietary Supplement Ingredients and Other Substances. Ingredient directory, entries for hordenine and L-DOPA. Content current as of 1 May 2026. Accessed 21 November 2026.
  35. Medicines and Healthcare products Regulatory Agency (2017). MHRA warns athletes to avoid potentially dangerous DMAA. Press release, 30 January 2017. Accessed 21 November 2026.
  36. Medicines and Healthcare products Regulatory Agency (2014). Medicines watchdog makes record seizure of experimental smart drugs. Press release, 24 October 2014. Accessed 21 November 2026.
  37. Medicines and Healthcare products Regulatory Agency (2021). Freedom of Information request on how many times have yohimbe/yohimbine, synephrine and ephedrine been reported to the Yellow Card Scheme since 2011 (FOI 21/779). Response of 5 August 2021, published 27 April 2022. Accessed 21 November 2026.
  38. European Union. Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other substances to foods. Annex III, consolidated text of 26 November 2025. Accessed 21 November 2026.
  39. European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 21 November 2026.
  40. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 21 November 2026.
  41. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 21 November 2026.